The relationship between chronic obstructive pulmonary disease (COPD) and chronic bronchitis (CB) is important, significant and overlapping in nature. This review will analyze the relationship ...

Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

“Oftentimes, most patients have both emphysema and chronic bronchitis, which is why we often just refer to it as COPD,” Dr. Beuther adds. About 3 out of 4 cases of COPD are caused by smokin ...

The US Food and Drug Administration (FDA) has approved mepolizumab as a maintenance treatment for chronic obstructive ...

Nineteen patients had uncomplicated chronic bronchitis. In 11 the disease was associated with emphysema. The subjects presented a wide spectrum of disease, ranging from early or minimal to long ...

Patients with COPD and type 2 inflammation receiving mepolizumab vs. placebo had decreased moderate and severe exacerbation ...

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic ...

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved ...

With proper management, most allergic bronchitis patients achieve good symptom control and prevent progression to chronic conditions. Early recognition of warning signs, prompt treatment ...